{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:39:21Z","timestamp":1772429961797,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.humpath.2010.10.025","type":"journal-article","created":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T10:29:00Z","timestamp":1297506540000},"page":"1019-1026","source":"Crossref","is-referenced-by-count":48,"title":["Class III \u03b2-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance"],"prefix":"10.1016","volume":"42","author":[{"given":"Thea Eline","family":"Hetland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Hellesylt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivi Ann","family":"Fl\u00f8renes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"K\u00e6rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2010.10.025_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"10.1016\/j.humpath.2010.10.025_bb0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0020-7292(03)90118-4","article-title":"Carcinoma of the ovary","volume":"83","author":"Heintz","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.humpath.2010.10.025_bb0015","series-title":"Practical Gynecological Oncology","first-page":"327","article-title":"Epithelial ovarian cancer","author":"Berek","year":"1994"},{"key":"10.1016\/j.humpath.2010.10.025_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.1995.1027","article-title":"The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer","volume":"56","author":"Makar","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevOncog.v13.i3.10","article-title":"Biological characteristics of cancers involving the serosal cavities","volume":"13","author":"Davidson","year":"2007","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.humpath.2010.10.025_bb0030","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2010.10.025_bb0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2010.10.025_bb0040","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2010.10.025_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00001622-200209000-00008","article-title":"Management of recurrent ovarian cancer: evidence-based decisions","volume":"14","author":"Salom","year":"2002","journal-title":"Curr Opin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.humpath.2010.10.025_bb0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6601494","article-title":"Primary ovarian cancer chemotherapy: current standards of care","volume":"89","author":"McGuire","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2010.10.025_bb0060","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","article-title":"Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis","volume":"26","author":"Eyler","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0065","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2010.10.025_bb0070","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and characterization of ovarian cancer-initiating cells from primary human tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2010.10.025_bb0075","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of Taxol resistance related to microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2010.10.025_bb0080","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1078-0432.298.11.1","article-title":"Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients","volume":"11","author":"Mozzetti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2010.10.025_bb0085","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-05-2715","article-title":"Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients","volume":"12","author":"Ferrandina","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2010.10.025_bb0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","article-title":"Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?","volume":"9","author":"Seve","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0095","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1172\/JCI119642","article-title":"Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes","volume":"100","author":"Kavallaris","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humpath.2010.10.025_bb0100","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cncr.24282","article-title":"Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel","volume":"115","author":"Su","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2010.10.025_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.humpath.2010.10.025_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2164-9-99","article-title":"Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids","volume":"9","author":"L'Esperance","year":"2008","journal-title":"BMC Genomics"},{"key":"10.1016\/j.humpath.2010.10.025_bb0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2407-5-101","article-title":"No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel\/cisplatin","volume":"5","author":"Mesquita","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2010.10.025_bb0120","first-page":"215","article-title":"Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers","volume":"1","author":"Sale","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2010.10.025_bb0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2005.05.025","article-title":"beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues","volume":"236","author":"Green","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2010.10.025_bb0130","first-page":"1227","article-title":"Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells","volume":"32","author":"Izutsu","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0135","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/00000478-200111000-00008","article-title":"The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells","volume":"25","author":"Davidson","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2010.10.025_bb0145","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2010.10.025_bb0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1582-4934.2005.tb00376.x","article-title":"Novel type of interstitial cell (Cajal-like) in human fallopian tube","volume":"9","author":"Popescu","year":"2005","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.humpath.2010.10.025_bb0155","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/onc.2010.35","article-title":"CD24(+) cells from hierarchically organized ovarian cancer are enriched in cancer stem cells","volume":"29","author":"Gao","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2010.10.025_bb0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1006711320107","article-title":"Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma\u2014diagnostic and prognostic implications","volume":"18","author":"Berner","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.humpath.2010.10.025_bb0165","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/jcp.2008.058750","article-title":"Nestin is expressed in basal-like and triple negative breast cancers","volume":"61","author":"Parry","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PGP.0b013e31818b0f5e","article-title":"Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma","volume":"28","author":"Elstrand","year":"2009","journal-title":"Int J Gynaecol Pathol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0175","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.humpath.2009.09.017","article-title":"Mammalian target of rapamycin is a biomarker of poor survival in metastatic ovarian carcinoma","volume":"41","author":"Bunkholt Elstrand","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1535-7163.MCT-08-0986","article-title":"Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies","volume":"8","author":"Dumontet","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2010.10.025_bb0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2009.24.1455","article-title":"Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study","volume":"28","author":"De Geest","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2010.10.025_bb0190","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1535-7163.MCT-09-0548","article-title":"Natural product derivative bis(4-fluorobenzyl)trisulfide inhibits tumor growth by modification of beta-tubulin at Cys 12 and suppression of microtubule dynamics","volume":"8","author":"Xu","year":"2009","journal-title":"Mol Cancer Ther"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771000417X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771000417X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T06:08:54Z","timestamp":1685945334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771000417X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S004681771000417X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2010.10.025","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}